Moreover, the MMSE might not be an optimal measure of global cognitive decline in probable DLB,40 although some studies have suggested otherwise.41 Most importantly, these clinical and cognitive measures may be influenced by other pathologies, such as NFT-tau or α-synuclein, or by other neurologic and functional factors, such as mood or daytime sleepiness. The gene discussed is MAPT; the disease is Lewy body dementia.